Last update 05 Nov 2024

Pantoprazole Sodium Hydrate

Last update 05 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryPantoprazole is a small molecule medicine classed as a proton pump inhibitor, which means it reduces the amount of acid generated in the stomach. Takeda Pharmaceutical Co., Ltd. authorized this drug for the first time in January 1994. Pantoprazole is exceptionally efficient in treating disorders such as peptic ulcer bleeding, which is characterized by excessive acid output, resulting in stomach lining erosion. It is also used to treat fasting when acid secretion can cause pain and bleeding. Generally speaking, Pantoprazole is well-tolerated and has minimal adverse effects, making it a common therapy choice for acid-related diseases.

Drug Type

Small molecule drug

Synonyms

Anagastra, Controloc, Eupantol

+ [51]

Target

Proton pump

Mechanism

Proton pump inhibitors

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders+ [4]

Active Indication

Erosive esophagitisGastroesophageal RefluxHelicobacter pylori infection+ [6]

Inactive Indication

Chronic peptic ulcerFastingHemorrhage+ [4]

Originator Organization

Takeda Pharmaceutical Co., Ltd.

Active Organization

Takeda Pharmaceuticals Australia Pty Ltd.Wyeth Pharmaceuticals LLCTakeda GmbH

+ [7]

Inactive Organization

Takeda Pharmaceutical Co., Ltd.Wyeth ABDr. Reddy's Laboratories Ltd. (Russia)

+ [3]

Drug Highest PhaseApproved

First Approval Date

DE (01 Jan 1994),

Ulcer

RegulationPriority Review (CN)

Structure

Molecular FormulaC16H17F2N3NaO5S

InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N

CAS Registry164579-32-2

265

Clinical Trials associated with Pantoprazole Sodium Hydrate

IRCT20200623047902N7 / Suspended

Bioequivalence study of Pantoprazole 40 mg tablet manufactured by Sanamed company versus the originator brand in fed and fast condition in healthy volunteers

Start Date22 Oct 2024

Sponsor / Collaborator-

NCT06531642 / RecruitingPhase 2/3IIT

Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury (CEPU-AKI) in Hemorrhagic Shock Patients: a Prospective Randomized Controlled Trial

The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific aims of the study will be achieved by a cohort of 100 patients to receive either early(study) or routine (control) administration of pantoprazole for 2 days after the initial injury insult.

Start Date07 Sep 2024

Sponsor / Collaborator

University of Texas Health Science Center at Houston

[+1]

CTR20242757 / Active, not recruitingNot Applicable

泮托拉唑钠肠溶片人体生物等效性研究

[Translation] Study on the bioequivalence of pantoprazole sodium enteric-coated tablets in healthy volunteers

本试验旨在研究单次空腹口服 Krka, d. d., Novo mesto, Slovenia, EU 研制、生产的泮托拉唑钠肠溶片（40 mg）的药代动力学特征；以 Takeda GmbH Production Site Oranienburg 生产的泮托拉唑钠肠溶片（Pantoloc®，40 mg）为参比制剂，比较两制剂中药动学参数 Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性

[Translation]

The aim of this study was to investigate the pharmacokinetic characteristics of pantoprazole sodium enteric-coated tablets (40 mg) developed and produced by Krka, d. d., Novo mesto, Slovenia, EU after a single fasting oral administration; pantoprazole sodium enteric-coated tablets (Pantoloc®, 40 mg) produced by Takeda GmbH Production Site Oranienburg was used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date26 Aug 2024

Sponsor / Collaborator

Ningbo Krka Menovo Pharmaceutical Co., Ltd.

100 Clinical Results associated with Pantoprazole Sodium Hydrate

100 Translational Medicine associated with Pantoprazole Sodium Hydrate

100 Patents (Medical) associated with Pantoprazole Sodium Hydrate

2,233

Literatures (Medical) associated with Pantoprazole Sodium Hydrate

01 Jan 2025·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Design and synthesis of high quantum yield doped carbon nano probe derived from household sources for sensing of the anti-GERD drug pantoprazole

Article

Author: El-Maghrabey, Mahmoud ; El-Shaheny, Rania ; Magdy, Galal ; Al-Khateeb, Lateefa A ; Alshehri, Sultan ; Mahdi, Wael A. ; Alsehli, Bandar R. ; Alsehli, Bandar R ; El Hamd, Mohamed A. ; El Hamd, Mohamed A ; Al-Khateeb, Lateefa A. ; Mahdi, Wael A

This contribution aims to design and validate a new green, cheap, and fast approach for determining the anti-GERD drug pantoprazole in different matrices. New S and N-doped carbon nanomaterials (S,N-CNMs) have been prepared via microwave irradiation of a mixture of widely available household sources. Remarkably, the utilization of a blend of carbamide and thiocarbamide with table sugar yields S,N-CNMs exhibiting the utmost quantum yield (54 %), hydrophilicity, as well as stable, homogeneous, and diminutive particle size distribution. Fourier transform infrared spectroscopy, transmission electron microscopy, spectrophotometry, and fluorescence spectroscopy were applied to characterize the S,N-CNMs. The S,N-CNMs have been used as a turn-off fluorescence probe to determine pantoprazole via a synergism of the inner filter effect and static quenching mechanisms. The fluorescence quenching is linearly correlated to pantoprazole concentration over the range of 1.0-25.0 µg/mL with a detection limit of 0.16 µg/mL. The developed probe exhibited good selectivity for pantoprazole in the presence of variability of substances. Therefore, it was applied for quality control of pantoprazole in pharmaceutical tablets and vials with an average recovery % of 100.10 ± 0.77 % and 100.33 ± 0.92 %, respectively. Moreover, it was successfully implemented to examine the content uniformity of pantoprazole in tablets. Furthermore, the prepared S,N-CNMs have been successfully used for the analysis of pantoprazole in human plasma after a simple protein precipitation step with a recovery % of 97.88 ± 5.72 %. The greenness and blueness of the developed method have been positively assessed by recent tools showing the eco-friendliness and applicability of the developed method.

31 Dec 2024·Gut Microbes

Efficacy of an inulin-based treatment on intestinal colonization by multidrug-resistant E. coli: insight into the mechanism of action

Article

Author: Montassier, Emmanuel ; Dion, Michel ; Batard, Eric ; Ishnaiwer, Murad ; Zeman, Michal ; Le Bastard, Quentin ; Naour, Maxime ; Dailly, Eric

Inulin, an increasingly studied dietary fiber, alters intestinal microbiota. The aim of this study was to assess whether inulin decreases intestinal colonization by multidrug resistant E. coli and to investigate its potential mechanisms of action. Mice with amoxicillin-induced intestinal dysbiosis mice were inoculated with extended spectrum beta-lactamase producing E. coli (ESBL-E. coli). The combination of inulin and pantoprazole (IP) significantly reduced ESBL-E. coli fecal titers, whereas pantoprazole alone did not and inulin had a delayed and limited effect. Fecal microbiome was assessed using shotgun metagenomic sequencing and qPCR. The efficacy of IP was predicted by increased abundance of 74 taxa, including two species of Adlercreutzia. Preventive treatments with A. caecimuris or A. muris also reduced ESBL-E. coli fecal titers. Fecal microbiota of mice effectively treated by IP was enriched in genes involved in inulin catabolism, production of propionate and expression of beta-lactamases. They also had increased beta-lactamase activity and decreased amoxicillin concentration. These results suggest that IP act through production of propionate and degradation of amoxicillin by the microbiota. The combination of pantoprazole and inulin is a potential treatment of intestinal colonization by multidrug-resistant E. coli. The ability of prebiotics to promote propionate and/or beta-lactamase producing bacteria may be used as a screening tool to identify potential treatments of intestinal colonization by multidrug resistant Enterobacterales.

01 Dec 2024·Molecular biology reports

Aloe vera gel confers therapeutic effect by reducing pyroptosis in ethanol-induced gastric ulcer rat model: Role of NLRP3/GSDMD signaling pathway

Article

Author: Mohamed, Amany O ; Kamel, Amira A ; Abd-Elghaffar, Sary Kh ; Mousa, Rehab A

Abstract:

Background:

Gastric ulcer (GU) is a common gastrointestinal tract illness. Aloe vera has anti-inflammatory, antioxidant, and healing characteristics. This research sought to explore the therapeutic impact of Aloe vera gel on ethanol-provoked GU in rats and to elucidate the underlying mechanisms involved.

Methods:

An ethanol-induced GU rat model was constructed using forty male Wistar rats distributed at random into four groups: control, ulcer, pantoprazole, and Aloe vera. Gross evaluation of the stomach, ulcer index (UI), inhibition index, and gastric pH estimation were analyzed. Gastric malondialdehyde (MDA) and reduced glutathione (GSH) were determined using the spectrophotometric method, and serum gastrin level was measured by an enzyme-linked immunosorbent assay. Gastric nucleotide-binding domain, leucine-rich repeat, and pyrin domain PYD containing protein 3 (NLRP3) and gasdermin D (GSDMD) mRNA expression levels were estimated by quantitative real-time PCR. Finally, the histopathological examination of the glandular part of stomach tissue was done.

Results:

The ulcer group revealed a significant increase in MDA, gastrin, NLRP3, and GSDMD and a decrease in gastric pH and GSH compared to the control group. Gross investigations of the ulcer group revealed a hemorrhagic lesion in the stomach and an increase in UI. Also, histopathological results for this group showed severe epithelial loss, haemorrhage, inflammatory cell infiltration, and blood vessel congestion. However, Aloe vera treatment improved the gross, biochemical, molecular, and histopathological alterations induced by ethanol when compared to the ulcer group.

Conclusions:

Aloe vera exerted antiulcer activities through modulation of oxidant/antioxidant status, anti-secretory properties, and mitigation of pyroptosis.

News (Medical) associated with Pantoprazole Sodium Hydrate

17 Jun 2024

·www.drugs.com

Pantoprazole Cuts GI Bleeding in Patients Undergoing Invasive Ventilation

MONDAY, June 17, 2024 -- Pantoprazole results in a significantly lower risk for clinically important upper gastrointestinal bleeding than placebo, with no increase in mortality, among patients undergoing invasive ventilation, according to a study published online June 14 in the New England Journal of Medicine to coincide with the annual Critical Care Reviews Meeting, held from June 12 to 14 in Belfast, Northern Ireland. Deborah Cook, M.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues assigned critically ill adults who were undergoing invasive ventilation to receive intravenous pantoprazole (40 mg daily) or matching placebo in an international randomized trial. Overall, 4,821 patients in 68 intensive care units were randomly assigned. The researchers found that clinically important upper gastrointestinal bleeding occurred in 25 of 2,385 and 84 of 2,377 patients receiving pantoprazole and placebo, respectively (1.0 versus 3.5 percent; hazard ratio, 0.30; 95 percent confidence interval, 0.19 to 0.47; P < 0.001). Death from any cause at 90 days was reported in 29.1 and 30.9 percent of patients in the pantoprazole and placebo groups, respectively (hazard ratio, 0.94; 95 percent confidence interval, 0.85 to 1.04; P = 0.25). There was a reduction in patient-important bleeding with pantoprazole, but other key secondary outcomes did not differ between the groups. "The use of pantoprazole resulted in a lower risk of clinically important upper gastrointestinal bleeding than the use of placebo, with no overall effect on mortality," the authors write.

Clinical Result

14 Jun 2024

·www.sciencedaily.com

Global trial confirms benefit of antacids on bleeding prevention for ventilated patients

Critically ill patients are at risk of stress-induced upper gastrointestinal bleeding. Now, a global trial confirms that a widely available drug does prevent upper gastrointestinal bleeding. A widely available drug helps prevent upper gastrointestinal bleeding in critically ill adults on a breathing machine, according to the results of a global study and meta-analysis led by researchers at McMaster University. The research, published on June 14, 2024 in The New England Journal of Medicine and NEJM Evidence, investigated the effect of the gastric acid suppressant pantoprazole, which is primarily used to treat heartburn caused by gastroesophageal reflux disease (GERD). Patients in the intensive care unit (ICU) who need a breathing machine (mechanical ventilator) also receive pantoprazole to prevent upper gastrointestinal bleeding, caused by stress-induced ulcers in the stomach. Concerns emerged about whether this complication of critical illness had disappeared over the years, and about side effects of pantoprazole, including increased risk of death in the sickest patients. The research provides critical care teams with certainty about whether the medications should be used in practice. "This is the largest randomized trial on this topic in the world, led by Canada. Physicians, nurses, and pharmacists working in the ICU setting will use this information in practice right away, and the trial results and the updated meta-analysis will be incorporated into international practice guidelines," said lead author and principal investigator Deborah Cook, a professor in the Department of Medicine at McMaster. Global randomized control trial The Reevaluating the Inhibition of Stress Erosions (REVISE) Trial was a randomized control trial that compared the effect of pantoprazole to placebo in critically ill adults on a breathing machine. The trial was run in 68 centres in eight countries and over 4,800 patients underwent randomization. Among patients undergoing invasive ventilation, pantoprazole resulted in a significantly lower risk of clinically important upper gastrointestinal bleeding than placebo but not in a lower risk of death. Clinically important upper gastrointestinal bleeding occurred in 25 of 2,417 patients (one per cent) receiving pantoprazole and in 84 of 2404 patients (nearly four per cent) receiving placebo. At 90 days, death was reported in 696 of 2390 patients (29 per cent) in the pantoprazole group and in 734 of 2379 patients (30 per cent) in the placebo group. Updated systematic review Researchers conducted a meta-analysis of 12 randomized trials of proton-pump inhibitors for GI bleeding prevention in 10,000 critically ill patients to summarize the current evidence on the outcomes of gastrointestinal bleeding, mortality, pneumonia and C. difficile infection. The medications were associated with a reduced incidence of clinically important upper gastrointestinal bleeding and may have little or no effect on mortality. The evidence also showed the medications may have no effect on pneumonia and little or no effect on C. difficile infection. The research was funded by the Canadian Institutes for Health Research, the Accelerating Clinical Trials Fund, Physicians Services Incorporated of Ontario, Hamilton Association of Health Sciences Organization, and the National Health Medical Research Council of Australia.

Clinical Result

19 Dec 2023

·www.prnewswire.com

Proton Pump Inhibitors (PPIs) Market to grow by USD 807.89 million from 2023-2028 | North America to account for 36% of market growth - Technavio

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- The proton pump inhibitors (PPIs) market size is expected to grow by USD 807.89 million from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 4.86% during the forecast period, according to Technavio Research. The market is categorized by Product (OTC PPIs and Prescription PPIs), Route Of Administration (Oral and Injectable), and Geography (North America, Europe, Asia, and Rest of World (ROW)). North America will contribute 36% to the growth of the global market during the forecast period. Factors such as the presence of large pharmaceutical companies that offer both branded and generic PPIs and the presence of a proper regulatory framework for the approval of new drugs in the region drive regional market growth. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a FREE PDF Sample Report Continue Reading Technavio has announced its latest market research report titled Global Proton Pump Inhibitors (PPIs) Market 2024-2028 Company Profile: Amgen Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Bayer AG, Cipla Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Perrigo Co. Plc, Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., The Procter and Gamble Co., Zydus Lifesciences Ltd. Amgen Inc. - The company offers proton pump inhibitors such as LUMAKRAS with gastric acid-reducing agents and decreased sotorasib concentrations. To gain access to more vendor profiles available with Technavio, buy the report! Proton Pump Inhibitors (PPIs) Market: Health Analysis Proton Pump Inhibitors (PPIs) play a significant role in managing various gastrointestinal conditions, including Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis, effectively suppressing acid production. Helicobacter pylori, a common bacterium, often contributes to Peptic Ulcer Disease, for which both prescription and non-prescription PPIs are used as part of the treatment regimen, ensuring comprehensive therapy against this bacterial infection. The Proton Pump Inhibitor Market showcases a diverse range of medications, including FDA-approved and generic PPIs, aiming to alleviate symptoms associated with acid-related disorders like Heartburn, Erosive Esophagitis, and NSAID-Induced Ulcers. Understanding the potential side effects of Proton Pump Inhibitors is crucial, as they are associated with complications such as Duodenal Ulcers, necessitating careful consideration of their usage and monitoring for optimal gastrointestinal health. Heartburn, often associated with Acid-related Disorders, manifests as a burning sensation in the chest due to stomach acid reflux into the esophagus. This common symptom occurs post-meals, triggered by specific foods or lying down, contributing significantly to Acid-related Disorders' discomfort. Managing heartburn involves dietary modifications, maintaining an upright posture after eating, and utilizing medications to mitigate stomach acid production. Chronic heartburn, if left unaddressed, may lead to erosive esophagitis or Barrett's esophagus, highlighting its role within Acid-related Disorders and emphasizing the need for prompt intervention to alleviate symptoms and prevent complications. Proton Pump Inhibitors (PPIs) Market: Segmentation Analysis The OTC PPIs segment will be significant during the forecast period. The products in this segment are defined as medicines that are sold directly to patients or consumers without a prescription from a healthcare professional. Furthermore, the availability of OTC PPIs provides patients with an option for self-medication and reduces the financial burden associated with medication treatment. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report These six medications—Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole, and Dexlansoprazole—belong to the class of proton pump inhibitors, commonly prescribed to treat various gastrointestinal conditions by reducing stomach acid production. Each drug within this group exhibits distinct pharmacokinetic properties and efficacy profiles, catering to individual patient needs for managing acid-related disorders. "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Proton Pump Inhibitors (PPIs) Market: Driver & Trend: Driver Reformulation of drugs Growth in prescription rate Strong prevalence of gastroesophageal reflux disease Reformulation of drugs drives market growth. It provides an opportunity to grab patent term extensions, which can delay the entry of generic versions into the market. The availability of two dosage forms, NEXIUM 10 mg and 20 mg, will increase the consumption of the drug for various indications, particularly acid-related diseases, in both children aged one year and above the older patients with difficulty in swallowing. The rising prevalence of obesity is a leading market trend. Identify key trends, drivers, and challenges in the market. Download a sample report to gain access to this information. Unraveling Therapeutic Efficacy and Potential Complications in Gastrointestinal Health The Proton Pump Inhibitors (PPIs) Market comprises an extensive range of medications tailored to manage diverse acid-related disorders like Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease, and Gastritis. FDA-approved prescription PPIs play a significant role in treating conditions such as Zollinger-Ellison Syndrome and NSAID-Induced Ulcers, contributing significantly to gastrointestinal health and acid suppression. It's essential to recognize that both non-prescription and generic PPIs exist within this market, each exhibiting distinct efficacy profiles and potential side effects, including complications associated with prolonged use such as erosive esophagitis. Understanding the complexities of these medications is crucial for addressing various conditions and ensuring patient well-being amid the dynamic landscape of Proton Pump Inhibitors (PPIs) Market. Related Reports: The tyrosine kinase inhibitors market is estimated to grow at a CAGR of 8.93% between 2022 and 2027. The market size is forecasted to increase by USD 24.12 billion. The global PARP (poly ADP-ribose polymerase) inhibitors market size is estimated to grow by USD 5,555.99 million at a CAGR of 13.25% between 2023 and 2028. What are the key data covered in this proton pump inhibitors (PPIs) market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the proton pump inhibitors (PPIs) market between 2023 and 2028. Precise estimation of the proton pump inhibitors (PPIs) market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the proton pump inhibitors (PPIs) market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of proton pump inhibitors (PPIs) market vendors. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Product Market Segmentation by Route of Administration Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Pantoprazole Sodium Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02593	Pantoprazole Sodium Hydrate	A02BC02	DB00213

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erosive esophagitis	US	Wyeth Pharmaceuticals LLC	12 Jun 2001
Gastroesophageal Reflux	AU	Takeda Pharmaceuticals Australia Pty Ltd.	08 Jul 1999
Helicobacter pylori infection	AU	Takeda Pharmaceuticals Australia Pty Ltd.	08 Jul 1999
Duodenal Ulcer	CN	Liaoning Novino Pharmaceutical Co., Ltd	01 Jan 1998
Esophagitis, Peptic	CN	Liaoning Novino Pharmaceutical Co., Ltd	01 Jan 1998
Stomach Ulcer	CN	Liaoning Novino Pharmaceutical Co., Ltd	01 Jan 1998
Zollinger-Ellison Syndrome	CN	Liaoning Novino Pharmaceutical Co., Ltd	01 Jan 1998
Ulcer	DE	-	01 Jan 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peptic Ulcer	NDA/BLA	CN	Hetero Labs Ltd.	05 May 2022
Peptic Ulcer	NDA/BLA	CN	Benova(Tianjin)Innovation Pharmaceutical Research Co., Ltd.	05 May 2022
Hemorrhage	Phase 3	CN	Nanjing Yoko Pharmaceutical Group Co. Ltd.	24 Apr 2018
Hemorrhage	Phase 3	CN	Guangdong South China New Drug Creation Center	24 Apr 2018
Upper gastrointestinal hemorrhage	Phase 3	CN	Jiangsu Aosaikang Pharmaceutical Co. Ltd.	13 Nov 2015
Esophagitis	Phase 3	AR	Takeda Pharmaceutical Co., Ltd.	01 May 2006
Esophagitis	Phase 3	AU	Takeda Pharmaceutical Co., Ltd.	01 May 2006
Esophagitis	Phase 3	AT	Takeda Pharmaceutical Co., Ltd.	01 May 2006
Esophagitis	Phase 3	BE	Takeda Pharmaceutical Co., Ltd.	01 May 2006
Esophagitis	Phase 3	BR	Takeda Pharmaceutical Co., Ltd.	01 May 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02685748 (CTgov)	Phase 2/3	Schizophrenia \| Psychotic Disorders	60	Placebo	nxencoqrgx(nnyuhqpokt) = xodwxpwpxs xtclrzfayp (hcgadozbyx, ycdmrttrpp - qulwkvsolh) View more	-	23 Sep 2024
NCT01776424 (COMPASS, Pubmed)	Phase 3	Kidney Diseases	-	Pantoprazole	slgvseguuz(hzfmjrjwiu): OR = 0.89 (95% CI, 0.65 - 1.21) View more	Negative	11 Apr 2024
				Placebo
NCT02401035 (CTgov)	Phase 4	Gastroesophageal Reflux	19	pantoprazole sodium (Cohort 1 (>=1 to < 2 Years))	hnrrpycgad(oxctazfpgw) = yczpbmufwu ikdolsezia (cnhyokbvqa, sbgnznthzf - ibunzotyoq) View more	-	09 Apr 2024
				pantoprazole sodium (Cohort 2 (>=2 to <16 Years))	hnrrpycgad(oxctazfpgw) = hefbgyybyg ikdolsezia (cnhyokbvqa, xlkfcuxdla - lrlgyincum) View more
FDA Manual	Not Applicable	Zollinger-Ellison Syndrome	35	pantoprazole sodium	qywmrvchxz(imwpmtuzwm) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration xwlprxrtvc (twsakxyanh ) View more	Positive	14 Feb 2024
FDA Manual	Not Applicable	Gastroesophageal Reflux	143	pantoprazole sodium (Oral)	vvmlzmscyf(iuoffotgwg) = pbadytmwmu ddvmunanuy (uqnptdqevo ) View more	Positive	14 Feb 2024
				pantoprazole sodium (Intravenous)	vvmlzmscyf(iuoffotgwg) = uwulanwhba ddvmunanuy (uqnptdqevo ) View more
COMPASS (ASN2022)	Not Applicable	Kidney Diseases	-	Pantoprazole 40 mg daily	sjpljszyvm(cfgqhgmdax) = fnckyjrjma zoblnviavu (gybpmittaq, 4.27)	-	03 Nov 2022
				Placebo	sjpljszyvm(cfgqhgmdax) = ncymkyeuee zoblnviavu (gybpmittaq, 4.29)
NCT02467621 (SUP-ICU, Pubmed \| Intensive Care Med)	Phase 4	Upper gastrointestinal hemorrhage	3,298	Pantoprazole	ppttahwcwq(omwvgxfvkk): € = 1954	Negative	05 Feb 2022
				Placebo
CTRI/2018/02/011824 (ESMO2021)	Phase 1/2	Advanced Head and Neck Squamous Cell Carcinoma First line	120	Chemotherapy alone	nzbtfeetdn(myjuufblgf) = lkcneqxyvj uikgjbnppz (ymntlfemcf ) View more	Negative	16 Sep 2021
				Intravenous pantoprazole with chemotherapy	nzbtfeetdn(myjuufblgf) = lxsccdegrc uikgjbnppz (ymntlfemcf ) View more
NCT02432456 (CTgov)	Phase 4	Rib Fractures \| Acute Pain	153	Opioid+Acetaminophen+Pantoprazole+Methocarbamol+Ibuprofen (Placebo Infusion)	ljaehfnoau(znrhaugcxe) = mijftqpniq mayxvgwaix (hlzerreouq, pcisfbusjf - cjcfyptmfq) View more	-	05 Feb 2020
				Opioid+Acetaminophen+Pantoprazole+Methocarbamol+Ibuprofen+Ketamine (Ketamine Infusion)	ljaehfnoau(znrhaugcxe) = myifoujdff mayxvgwaix (hlzerreouq, rixlbrqpqt - adpifuxjom) View more
NCT02467621 (SUP-ICU, Pubmed \| Acta Anaesthesiol Scand)	Phase 4	Upper gastrointestinal hemorrhage	3,291	Pantoprazole 40 mg	pnfcprgarp(nnmotgjcap) = ivixmtfeor mvrunhecpi (zhvznugwuf )	-	01 Oct 2019
				Placebo (saline)	pnfcprgarp(nnmotgjcap) = joeyqmfydi mvrunhecpi (zhvznugwuf )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis